

The **AI in Drug Discovery Analytics Platform** is an advanced initiative by **Deep Pharma Intelligence (DPI)**, designed to provide cutting-edge insights into the rapidly evolving AI-driven pharmaceutical sector.

By leveraging Big Data analytics and AI-driven tools, the platform enables stakeholders to track emerging trends, optimize investments, and accelerate innovation in drug discovery and development.



Company Directory

The Company Directory serves as a comprehensive database of AI pharma companies, categorized by their specialization in drug discovery, clinical trials, and pharmaceutical technology. It provides detailed profiles of leading firms, including their research focus, partnerships, funding rounds.

Investor Portal

The Investor Portal offers deep insights into investment opportunities in AI pharma, including drug discovery and pharmaceutical innovation. It provides access to a network of 3,800 AI pharma companies being tracked for investment potential, along with 4,900 investors monitoring market trends.

AI Hub Collaboration

The AI Hub Collaboration connects AI pharma startups, healthcare providers, biotech investors, and R&D institutions to foster innovation and strategic partnerships. It accelerates drug discovery through AI-powered research focused on novel target identification and molecule design.


**4,900
Investors**

**3,800
Companies**

**750
Personalities**


**600
Hubs**

AI Pharma Industry




[View site](#)

[View interactive mindmap](#)



This graph shows the different stages of drug development and how many companies are incorporating artificial intelligence at the respective stages of drug development. The biggest number of AI in Pharma companies that operate in the areas of **Early Drug Development** and **Data Processing** which improves and speeds up the discovery of novel molecules and their validation. The third place is taken by **Clinical Development**, where AI can assist in selecting only a specific diseased population for recruitment in Phase II and III of clinical trials. The next place are taken by **End-to-End Drug Development** and **Preclinical Development**, where AI is mainly used to predict if molecule will pass preclinical trials considering the genome profile of the target cell line.



At this graph you can see the application of drug discovery against different disease areas. The most popular areas are oncology, immunology, neurology and inflammation, while less popular ones are Cardiovascular, Gastro Intestinal, Orphan and Metabology diseases.

AI tools are increasingly being applied in drug discovery against different disease areas. One of the most popular areas is oncology. With this growing global burden of oncology diseases, discovery of cancer treatment is one of the most significant public health challenges of the 21st century. Immunology is in second place, and 21% of companies use their AI technologies for finding treatment of immunological diseases.



Deep Pharma Intelligence is building a sophisticated cloud-based engine for advanced market and business intelligence in various deeptech industries. We provide profound AI-driven insights on the private and public markets in the Tech industries via customized IT-Platforms and Dashboards.